GSK Acquires Elsie Biotechnologies for $50 Million to Elevate Oligonucleotide Pipeline
Acquisition of Elsie Biotechnologies is expected to strengthen GSK’s research capabilities in modulating gene expression through the use of oligonucleotide.
Acquisition of Elsie Biotechnologies is expected to strengthen GSK’s research capabilities in modulating gene expression through the use of oligonucleotide.